A Double Blind Study of Pembrolizumab+Docetaxel+Prednisone vs Placebo+Docetaxel+Prednisone in Patients with Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer who have Progressed on Next Generation Hormonal Agent (MK3475-921)
A Double Blind Study of Pembrolizumab+Docetaxel+Prednisone vs Placebo+Docetaxel+Prednisone in Patients with Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer who have Progressed on Next Generation Hormonal Agent (MK3475-921)
Trial Category:
Genitourinary
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
